Global Procedures for Fractures and Degenerative Disc Disease (North America, including Canada and the United States; Oceania, including Australia and New Zealand; Latin America, including Argentina, Mexico, Brazil and Other Countries; Europe, including Germany, Frange, the U.K., Italy, Spain, Belgium, the Netherlands, Denmark, Finland, Normway, Sweden, Austria, Switzerland and Portugal.)


Scope:
This report pertains to a forecast period of 10 years (2009 – 2019) for North America, including Canada and the United States; Oceania, including Australia and New Zealand; Latin America, including Argentina, Mexico, Brazil and Other Countries; Europe, including Germany, Frange, the U.K., Italy, Spain, Belgium, the Netherlands, Denmark, Finland, Normway, Sweden, Austria, Switzerland and Portugal.

Report Contents:
Market Forecast and Analysis
Identify Strategic Opportunities
Final Review and Market Release
Customer Feedback and Market Monitoring

Main Segments Included:
Fractures
Degenerative Disc Disease
Avascular Necrosis

Companies Included:
PharMEDium/B. Braun
International Medical Industries
Ameridose
Health Care Logistics
Baxa Corporation/Baxter International
Medi-Dose/EPS/Vu-Pak

Reasons To Buy:
This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on our “ground up” approach, which includes primary and secondary research methods.

Table Of Contents

TABLE OF CONTENTS I

LIST OF FIGURES V
LIST OF CHARTS IX

1.1 IDATA’S 9-STEP METHODOLOGY 13
1.1.1 Step 1: Project Initiation and Team Selection 13
1.1.2 Step 2: Prepare Data Systems and Perform Secondary Research 15
1.1.3 Step 3: Preparation for Interviews and Questionnaire Design 16
1.1.4 Step 4: Performing Primary Research 17
1.1.5 Step 5: Research Analysis: Establishing Baseline Estimates 19
1.1.6 Step 6: Market Forecast and Analysis 20
1.1.7 Step 7: Identify Strategic Opportunities 22
1.1.8 Step 8: Final Review and Market Release 23
1.1.9 Step 9: Customer Feedback and Market Monitoring 24

FRACTURES 25

2.1 INTRODUCTION 25
2.1.1 Incidence of Fractures 25
2.1.2 Soft Tissue Damage 25
2.2 NORTH AMERICA 26
2.2.1 Incidence of Fracture 26
2.2.2 Fracture Numbers by Type 27
2.2.3 Osteoporotic Fracture Numbers of the Smoking Population 28
2.2.4 Osteoporotic Fracture Numbers of the Diabetic Population 29
2.2.5 Osteoporotic Fracture Numbers of the Glucocorticoid User Population 30
2.2.6 Fractures with Displacement 31
2.2.7 Fractures with Soft Tissue Damage 31
2.3 OCEANIA 33
2.3.1 Incidence of Fracture 33
2.3.2 Fracture Numbers by Type 34
2.3.3 Smoking Fracture Numbers 35
2.3.4 Diabetes Fracture Numbers 36
2.3.5 Glucocorticoid User Fracture Numbers 37
2.3.6 Fractures with Displacement 38
2.3.7 Fractures with Soft Tissue Damage 38
2.4 LATIN AMERICA 40
2.4.1 Incidence of Fracture 40
2.4.2 Fracture Numbers by Type 41
2.4.3 Smoking Fracture Numbers 42
2.4.4 Diabetes Fracture Numbers 43
2.4.5 Glucocorticoid User Fracture Numbers 44
2.4.6 Fractures with Displacement 45
2.4.7 Fractures with Soft Tissue Damage 45
2.5 EUROPE 47
2.5.1 Incidence of Fracture 47
2.5.2 Fracture Numbers by Type 48
2.5.3 Smoking Fracture Numbers 50
2.5.4 Diabetes Fracture Numbers 51
2.5.5 Glucocorticoid Fracture Numbers 52
2.5.6 Fractures with Displacement 53
2.5.7 Fractures with Soft Tissue Damage 53

DEGENERATIVE DISC DISEASE 55

3.1 INTRODUCTION 55
3.1.1 Degenerative Disc Disease 55
3.1.1.1 Disc Herniation 55
3.1.1.2 Stenosis 55
3.1.1.3 Spondylolisthesis 56
3.1.1.4 Arthritis 56
3.1.2 Vertebral Compression Fracture 56
3.1.2.1 Osteoporosis 56
3.1.2.2 Vertebral Compression Fractures 56
3.1.3 Risk Factors 57
3.1.3.1 Degenerative Disc Disease 57
3.1.3.2 Vertebral Compression Fracture 57
3.2 UNITED STATES 58
3.3 AUSTRALIA 63
3.4 LATIN AMERICA 68
3.4.1 Argentina 68
3.4.2 Brazil 73
3.4.3 Mexico 78
3.5 EUROPE 83
3.5.1 Germany 83
3.5.2 France 88
3.5.3 United Kingdom 93
3.5.4 Italy 98
3.5.5 Spain 103
3.5.6 Belgium 108
3.5.7 Netherlands 113
3.5.8 Denmark 118
3.5.9 Finland 123
3.5.10 Norway 128
3.5.11 Sweden 133
3.5.12 Austria 138
3.5.13 Switzerland 143
3.5.14 Portugal 148

AVASCULAR NECROSIS 153

4.1 INTRODUCTION 153
4.2 NORTH AMERICA 154
4.3 OCEANIA 155
4.4 LATIN AMERICA 156
4.5 EUROPE 159

APPENDIX: STATISTICS 165

5.1 SMOKING STATISTICS 165
5.1.1 North America 165
5.1.2 Oceania 165
5.1.3 Latin America 166
5.1.4 Europe 166
5.2 DIABETES STATISTICS 167
5.2.1 North America 167
5.2.2 Oceania 167
5.2.3 Latin America 168
5.2.4 Europe 168

ABBREVIATIONS 169

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

2 Companies

Company Profiles


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.